{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:29:43Z","timestamp":1781598583805,"version":"3.54.5"},"reference-count":40,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JBM"],"DOI":"10.2147\/jbm.s317966","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T03:34:09Z","timestamp":1625110449000},"page":"529-550","source":"Crossref","is-referenced-by-count":10,"title":["Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma"],"prefix":"10.2147","volume":"Volume 12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-5287","authenticated-orcid":true,"given":"Karun","family":"Neupane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-777X","authenticated-orcid":true,"given":"Adeel","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-6973","authenticated-orcid":true,"given":"Tehniat","family":"Faraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Bahram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-3171","authenticated-orcid":true,"given":"Hamid","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","volume":"36","author":"Vogl","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"ref7","unstructured":"US-FDA. FDA grants accelerated approval to selinexor for multiple myeloma. 2019. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-selinexor-multiple-myeloma. Accessed December, 2020."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428194.2020.1775210","volume":"61","author":"Walker","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.2147\/OTT.S227166","volume":"13","author":"Malandrakis","year":"2020","journal-title":"Onco Targets Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.3390\/ijms21155192","volume":"21","author":"Abramson","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061473","volume":"12","author":"Cho","year":"2020","journal-title":"Cancers"},{"key":"ref13","unstructured":"US-FDA. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. 2020. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed November 25, 2020."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-019-01241-7","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"ref18","first-page":"429","volume":"4","author":"Trudel","year":"2020","journal-title":"HemaSphere"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","volume":"34","author":"Razak","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjh.15969","volume":"186","author":"Jakubowiak","year":"2019","journal-title":"Br J Haematol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"ref23","first-page":"84","volume":"101","author":"Bahlis","year":"2016","journal-title":"Haematologica Conf"},{"key":"ref24","first-page":"Cd004310","volume":"2013","author":"Ruiz Garcia","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","volume":"20","author":"Jatoi","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref26","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","volume":"15","author":"Andreyev","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1111\/ajco.12055","volume":"10","author":"Sun","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00520-010-0902-1","volume":"18","author":"Hovan","year":"2010","journal-title":"Support Care Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.7150\/jca.28399","volume":"10","author":"Park","year":"2019","journal-title":"J Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref32","volume-title":"Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma","year":"2014"},{"key":"ref33","volume-title":"Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma","year":"2014"},{"key":"ref34","first-page":"936","volume":"4","author":"Eliason","year":"2020","journal-title":"HemaSphere"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","volume":"105","author":"Popat","year":"2020","journal-title":"Haematologica"},{"key":"ref36","unstructured":"Accessdata.fda.gov. BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf. Accessed February 1, 2021."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-018-3546-8","volume":"98","author":"Goldschmidt","year":"2019","journal-title":"Ann Hematol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","volume":"130","author":"Machlus","year":"2017","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"}],"container-title":["Journal of Blood Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71217","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T03:34:23Z","timestamp":1625110463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/profile-and-management-of-toxicity-of-selinexor-and-belantamab-mafodot-peer-reviewed-fulltext-article-JBM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":40,"URL":"https:\/\/doi.org\/10.2147\/jbm.s317966","relation":{},"ISSN":["1179-2736"],"issn-type":[{"value":"1179-2736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}